125 related articles for article (PubMed ID: 11876506)
1. Ultrastructural characterization of murine limb buds after in vitro exposure to grepafloxacin and other fluoroquinolones.
Shakibaei M; Baumann-Wilschke I; Rücker M; Stahlmann R
Arch Toxicol; 2002 Jan; 75(11-12):725-33. PubMed ID: 11876506
[TBL] [Abstract][Full Text] [Related]
2. Effects of fluoroquinolones and magnesium deficiency in murine limb bud cultures.
Förster C; Rücker M; Shakibaei M; Baumann-Wilschke I; Vormann J; Stahlmann R
Arch Toxicol; 1998 Jun; 72(7):411-9. PubMed ID: 9708880
[TBL] [Abstract][Full Text] [Related]
3. Effects of moxifloxacin and clinafloxacin on murine limb buds cultured in regular and in magnesium-deficient medium.
Bode K; Kunz A; Baumann-Wilschke I; Shakibaei M; Stahlmann R
Arch Toxicol; 2010 Mar; 84(3):221-6. PubMed ID: 19949773
[TBL] [Abstract][Full Text] [Related]
4. The comparative arthropathy of fluoroquinolones in dogs.
Takizawa T; Hashimoto K; Minami T; Yamashita S; Owen K
Hum Exp Toxicol; 1999 Jun; 18(6):392-9. PubMed ID: 10413244
[TBL] [Abstract][Full Text] [Related]
5. Comparative grepafloxacin phototoxicity in mouse skin.
Owen K
J Antimicrob Chemother; 1998 Aug; 42(2):261-4. PubMed ID: 9738848
[TBL] [Abstract][Full Text] [Related]
6. A comparative study of the repeat dose toxicity of grepafloxacin and a number of other fluoroquinolones in rats.
Takizawa T; Hasimoto K; Itoh N; Yamashita S; Owen K
Hum Exp Toxicol; 1999 Jan; 18(1):38-45. PubMed ID: 10025367
[TBL] [Abstract][Full Text] [Related]
7. Comparison of antimycobacterial activity of grepafloxacin against Mycobacterium avium with that of levofloxacin: accumulation of grepafloxacin in human macrophages.
Hirota M; Totsu T; Adachi F; Kamikawa K; Watanabe J; Kanegasaki S; Nakata K
J Infect Chemother; 2001 Mar; 7(1):16-21. PubMed ID: 11406752
[TBL] [Abstract][Full Text] [Related]
8. Distribution characteristics of levofloxacin and grepafloxacin in rat kidney.
Ito T; Yano I; Masuda S; Hashimoto Y; Inui K
Pharm Res; 1999 Apr; 16(4):534-9. PubMed ID: 10227708
[TBL] [Abstract][Full Text] [Related]
9. Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin.
Barry AL; Fuchs PC
J Chemother; 1997 Feb; 9(1):9-16. PubMed ID: 9106012
[TBL] [Abstract][Full Text] [Related]
10. Transport characteristics of grepafloxacin and levofloxacin in the human intestinal cell line Caco-2.
Yamaguchi H; Yano I; Saito H; Inui K
Eur J Pharmacol; 2001 Nov; 431(3):297-303. PubMed ID: 11730721
[TBL] [Abstract][Full Text] [Related]
11. Secretory mechanisms of grepafloxacin and levofloxacin in the human intestinal cell line caco-2.
Yamaguchi H; Yano I; Hashimoto Y; Inui KI
J Pharmacol Exp Ther; 2000 Oct; 295(1):360-6. PubMed ID: 10992002
[TBL] [Abstract][Full Text] [Related]
12. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
Klepser ME; Ernst EJ; Petzold CR; Rhomberg P; Doern GV
Antimicrob Agents Chemother; 2001 Mar; 45(3):673-8. PubMed ID: 11181341
[TBL] [Abstract][Full Text] [Related]
13. Effects of enrofloxacin and ciprofloxacin hydrochloride on canine and equine chondrocytes in culture.
Egerbacher M; Edinger J; Tschulenk W
Am J Vet Res; 2001 May; 62(5):704-8. PubMed ID: 11341389
[TBL] [Abstract][Full Text] [Related]
14. Determining the frequency of resistance of Streptococcus pneumoniae to ciprofloxacin, levofloxacin, trovafloxacin, grepafloxacin, and gemifloxacin.
Evans ME
Eur J Clin Microbiol Infect Dis; 2001 Dec; 20(12):883-5. PubMed ID: 11837640
[TBL] [Abstract][Full Text] [Related]
15. Quinolone-induced arthropathy: exposure of magnesium-deficient aged rats or immature rats, mineral concentrations in target tissues and pharmacokinetics.
Förster C; Schwabe R; Lozo E; Zippel U; Vormann J; Günther T; Merker HJ; Stahlmann R
Arch Toxicol; 1997; 72(1):26-32. PubMed ID: 9458187
[TBL] [Abstract][Full Text] [Related]
16. In vitro susceptibility of anaerobes to quinolones in the United States.
Hecht DW; Wexler HM
Clin Infect Dis; 1996 Dec; 23 Suppl 1():S2-8. PubMed ID: 8953099
[TBL] [Abstract][Full Text] [Related]
17. Cotransport of macrolide and fluoroquinolones, a beneficial interaction reversing P-glycoprotein efflux.
Sikri V; Pal D; Jain R; Kalyani D; Mitra AK
Am J Ther; 2004; 11(6):433-42. PubMed ID: 15543082
[TBL] [Abstract][Full Text] [Related]
18. Possible role for the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin, and DU-6859a) in the treatment of anaerobic infections: review of current information on efficacy and safety.
Goldstein EJ
Clin Infect Dis; 1996 Dec; 23 Suppl 1():S25-30. PubMed ID: 8953103
[TBL] [Abstract][Full Text] [Related]
19. Safety profile of grepafloxacin compared with other fluoroquinolones.
Stahlmann R; Schwabe R
J Antimicrob Chemother; 1997 Dec; 40 Suppl A():83-92. PubMed ID: 9484877
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic role of P-glycoprotein in oral bioavailability and intestinal secretion of grepafloxacin in vivo.
Yamaguchi H; Yano I; Saito H; Inui K
J Pharmacol Exp Ther; 2002 Mar; 300(3):1063-9. PubMed ID: 11861816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
